Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients[Figure presented]

European Urology

Volumn 72, Issue 5, 2017, Pages 689-709

  Gandaglia, Giorgio ^a   Briganti, Alberto ^a   Clarke, Noel ^b   Karnes, R Jeffrey ^c   Graefen, Markus ^d   Ost, Piet ^e   Zietman, Anthony Laurence ^f   Roach, Mack ^g  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c MAYO CLINIC   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant radiotherapy; Prostate cancer; Radical prostatectomy; Radiotherapy; Salvage radiotherapy

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACUTE TOXICITY; ADJUVANT RADIOTHERAPY; ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLADDER INJURY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL EFFECTIVENESS; CLINICAL OBSERVATION; CLINICAL OUTCOME; COMPARATIVE EFFECTIVENESS; DIARRHEA; EMBASE; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; HUMAN; MALE; MALE SEXUAL DYSFUNCTION; MEDLINE; META ANALYSIS (TOPIC); PATIENT IDENTIFICATION; PATIENT SELECTION; PELVIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE ESCALATION; RADIATION INJURY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM INJURY; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; SALVAGE RADIOTHERAPY; SALVAGE THERAPY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TIME TO TREATMENT; TOXICITY; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; CLINICAL DECISION MAKING; MORTALITY; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

CLINICAL DECISION-MAKING; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 85011909715     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.01.039     Document Type: Article

References (119)

1. Mottet, N., Bellmunt, J., Bolla, M., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71 (2017), 618–629.
2. Hamdy, F.C., Donovan, J.L., Lane, J.A., et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375 (2016), 1415–1424.
3. Sineshaw, H.M., Gray, P.J., Efstathiou, J.A., Jemal, A., Declining use of radiotherapy for adverse features after radical prostatectomy: results from the national cancer data base. Eur Urol 68 (2015), 768–774.
4. Leyh-Bannurah, S.R., Gazdovich, S., Budaus, L., et al. Population-based external validation of the updated 2012 Partin tables in contemporary North American prostate cancer patients. Prostate 77 (2016), 105–113.
5. Mullins, J.K., Feng, Z., Trock, B.J., Epstein, J.I., Walsh, P.C., Loeb, S., The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 188 (2012), 2219–2224.
6. Bolla, M., van Poppel, H., Tombal, B., et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380 (2012), 2018–2027.
7. Wiegel, T., Bartkowiak, D., Bottke, D., et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66 (2014), 243–250.
8. Thompson, I.M., Tangen, C.M., Paradelo, J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181 (2009), 956–962.
9. Gandaglia, G., Cozzarini, C., Mottrie, A., et al. The role of radiotherapy after radical prostatectomy in patients with prostate cancer. Curr Oncol Rep, 17, 2015, 53.
10. van Stam, M.A., Aaronson, N.K., Pos, F.J., et al. The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol 70 (2016), 751–757.
11. Suardi, N., Gallina, A., Lista, G., et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol 65 (2014), 546–551.
12. Gandaglia, G., Lista, G., Fossati, N., et al. Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Prostate Cancer Prostatic Dis 19 (2016), 185–190.
13. Fossati, N., Karnes, R.J., Boorjian, S.A., et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. Eur Urol 71 (2017), 886–893.
14. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
15. Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
16. Ghadjar, P., Hayoz, S., Bernhard, J., et al. Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 33 (2015), 4158–4166.
17. Carrie, C., Hasbini, A., de Laroche, G., et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicentre, open-label phase 3 trial. Lancet Oncol 17 (2016), 747–756.
18. Shipley, W.U., Pugh, S.L., Lukka, H.R., et al. NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. J Clin Oncol, 34(Suppl 2S), 2016 abstr 3.
19. Abdollah, F., Karnes, R.J., Suardi, N., et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32 (2014), 3939–3947.
20. Briganti, A., Karnes, R.J., Da Pozzo, L.F., et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol 59 (2011), 832–840.
21. Kaplan, J.R., Kowalczyk, K.J., Borza, T., et al. Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy. BJU Int 111 (2013), 1208–1214.
22. Rusthoven, C.G., Carlson, J.A., Kavanagh, B.D., External validation of the benefit of adjuvant radiotherapy for pathologic N1M0 prostate cancer. J Clin Oncol 33 (2015), 1987–1988.
23. Tilki, D., Preisser, F., Tennstedt, P., et al. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU Int 119 (2017), 717–723.
24. Wong, A.T., Schwartz, D., Osborn, V., Safdieh, J., Weiner, J., Schreiber, D., Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer. Urol Oncol, 34, 2016 529.e15-29.
25. Budiharto, T., Perneel, C., Haustermans, K., et al. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 97 (2010), 474–479.
26. D'Amico, A.V., Chen, M.H., Sun, L., et al. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int 106 (2010), 1618–1622.
27. Detti, B., Scoccianti, S., Cassani, S., et al. Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307 patients with prostate cancer. J Cancer Res Clin Oncol 139 (2013), 147–157.
28. Jereczek-Fossa, B.A., Zerini, D., Vavassori, A., et al. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys 74 (2009), 115–125.
29. Mishra, M.V., Scher, E.D., Andrel, J., et al. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes. Am J Clin Oncol 38 (2015), 55–60.
30. Ost, P., De Troyer, B., Fonteyne, V., Oosterlinck, W., De Meerleer, G., A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 80 (2011), 1316–1322.
31. Abdollah, F., Suardi, N., Cozzarini, C., et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 63 (2013), 998–1008.
32. Den, R.B., Yousefi, K., Trabulsi, E.J., et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33 (2015), 944–951.
33. Gandaglia, G., Karakiewicz, P.I., Briganti, A., et al. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol 22 (2015), 89–95.
34. Van der Kwast, T.H., Bolla, M., Van Poppel, H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25 (2007), 4178–4186.
35. Ross, A.E., Den, R.B., Yousefi, K., et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis 19 (2016), 277–282.
36. Zhao, S.G., Chang, S.L., Spratt, D.E., et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol 17 (2016), 1612–1620.
37. Bottke, D., Golz, R., Storkel, S., et al. Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. Eur Urol 64 (2013), 193–198.
38. Bernard, J.R. Jr., Buskirk, S.J., Heckman, M.G., et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 76 (2010), 735–740.
39. Blanchard, P., Bakkour, M., De Crevoisier, R., et al. Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. Urol Oncol, 33, 2015 108.e15-20.
40. Briganti, A., Karnes, R.J., Joniau, S., et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 66 (2014), 479–486.
41. Cotter, S.E., Chen, M.H., Moul, J.W., et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 117 (2011), 3925–3932.
42. Ervandian, M., Hoyer, M., Petersen, S.E., et al. Salvage radiation therapy following radical prostatectomy. A national Danish study. Acta Oncol 55 (2016), 598–603.
43. Fossati, N., Karnes, R.J., Cozzarini, C., et al. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69 (2016), 728–733.
44. Goenka, A., Magsanoc, J.M., Pei, X., et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 84 (2012), 112–118.
45. Jackson, W., Hamstra, D.A., Johnson, S., et al. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer 119 (2013), 3287–3294.
46. Kwon, O., Kim, K.B., Lee, Y.I., et al. Salvage radiotherapy after radical prostatectomy: prediction of biochemical outcomes. PLoS One, 9, 2014, e103574.
47. Lohm, G., Lutcke, J., Jamil, B., et al. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy: long-term follow-up of a single-center survey. Strahlenther Onkol 190 (2014), 727–731.
48. Moreira, D.M., Jayachandran, J., Presti, J.C. Jr., et al. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int 104 (2009), 1452–1456.
49. Ost, P., Lumen, N., Goessaert, A.S., et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 60 (2011), 842–849.
50. Parekh, A., Chen, M.H., Graham, P., et al. Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. Clin Genitourin Cancer 13 (2015), e1–e6.
51. Ploussard, G., Staerman, F., Pierrevelcin, J., et al. Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. World J Urol 32 (2014), 1331–1338.
52. Siegmann, A., Bottke, D., Faehndrich, J., et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlenther Onkol 187 (2011), 467–472.
53. Song, W., Jeon, H.G., Sung, H.H., et al. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy. Int J Urol 23 (2016), 56–61.
54. Stish, B.J., Pisansky, T.M., Harmsen, W.S., et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol 34 (2016), 3864–3871.
55. Tendulkar, R.D., Agrawal, S., Gao, T., et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 34 (2016), 3648–3654.
56. Umezawa, R., Ariga, H., Ogawa, Y., et al. Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml. Radiat Oncol, 6, 2011, 150.
57. van der Poel, H.G., Tillier, C., de Blok, W., Acar, C., van Muilekom, E.H., Salvage radiotherapy after robot-assisted laparoscopic radical prostatectomy. Urology 82 (2013), 834–838.
58. Fiorino, C., Broggi, S., Fossati, N., et al. Predicting the 5-year risk of biochemical relapse after postprostatectomy radiation therapy in ≥PT2, pN0 patients with a comprehensive tumor control probability model. Int J Radiat Oncol Biol Phys 96 (2016), 333–340.
59. Sia, M., Rodrigues, G., Menard, C., et al. Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. Can Urol Assoc J 4 (2010), 105–111.
60. Ost, P., Fonteyne, V., Villeirs, G., Lumen, N., Oosterlinck, W., De Meerleer, G., Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 56 (2009), 669–675.
61. Alongi, F., Fiorino, C., Cozzarini, C., et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93 (2009), 207–212.
62. Cozzarini, C., Fiorino, C., Da Pozzo, L.F., et al. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients. Int J Radiat Oncol Biol Phys 82 (2012), 191–199.
63. Sowerby, R.J., Gani, J., Yim, H., Radomski, S.B., Catton, C., Long-term complications in men who have early or late radiotherapy after radical prostatectomy. Can Urol Assoc J 8 (2014), 253–258.
64. Hegarty, S.E., Hyslop, T., Dicker, A.P., Showalter, T.N., Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. PLoS One, 10, 2015, e0118430.
65. Showalter, T.N., Hegarty, S.E., Rabinowitz, C., et al. Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy. Int J Radiat Oncol Biol Phys 91 (2015), 752–759.
66. Cozzarini, C., Fiorino, C., Deantoni, C., et al. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 66 (2014), 1024–1030.
67. Goenka, A., Magsanoc, J.M., Pei, X., et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 60 (2011), 1142–1148.
68. Cremers, R.G., van Lin, E.N., Gerrits, W.L., et al. Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy. Radiother Oncol 97 (2010), 467–473.
69. Jereczek-Fossa, B.A., Ciardo, D., Ferrario, S., et al. No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. Br J Radiol, 89, 2016, 20150985.
70. Van Praet, C., Ost, P., Lumen, N., et al. Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy. Radiother Oncol 109 (2013), 222–228.
71. Zaffuto, E., Gandaglia, G., Fossati, N., et al. Early post-operative radiotherapy is associated with worse functional outcomes in prostate cancer patients. J Urol 197 (2017), 669–675.
72. Abdel-Wahab, M., Reis, I.M., Wu, J., Duncan, R., Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urology 74 (2009), 866–871.
73. Ciezki, J.P., Reddy, C.A., Angermeier, K., Twenty-year competing risk analysis of secondary malignancies after external beam radiation for postoperative treatment of prostate cancer patients from the SEER database. Int J Radiat Oncol Biol Phys 84 (2012), S14–S16.
74. Singh, A.K., Mashtare, T.L., McCloskey, S.A., Seixas-Mikelus, S.A., Kim, H.L., May, K.S., Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis. Int J Radiat Oncol Biol Phys 78 (2010), 1086–1094.
75. Imnadze, M., Sjoberg, D.D., Vickers, A.J., Adverse pathologic features at radical prostatectomy: effect of preoperative risk on oncologic outcomes. Eur Urol 69 (2016), 143–148.
76. Reese, A.C., Wessel, S.R., Fisher, S.G., Mydlo, J.H., Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry. Urol Oncol, 34, 2016 335.e21-8.
77. Boorjian, S.A., Eastham, J.A., Graefen, M., et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 61 (2012), 664–675.
78. Swanson, G.P., Hussey, M.A., Tangen, C.M., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007), 2225–2229.
79. Nini, A., Gandaglia, G., Fossati, N., et al. Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival. Eur Urol 68 (2015), 777–784.
80. van Leeuwen, P.J., Stricker, P., Hruby, G., et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117 (2016), 732–739.
81. Meijer, H.J., van Lin, E.N., Debats, O.A., et al. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 82 (2012), 1405–1410.
82. Thompson, I.M., Valicenti, R.K., Albertsen, P., et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 190:2 (2013), 441–449.
83. Bolla, M., van Poppel, H., Collette, L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005), 572–578.
84. Wiegel, T., Bartkowiak, D., Bottke, D., et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys 91 (2015), 288–294.
85. Daly, T., Hickey, B.E., Lehman, M., Francis, D.P., See, A.M., Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev, 12, 2011, CD007234.
86. Stephenson, A.J., Bolla, M., Briganti, A., et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 61 (2012), 443–451.
87. Moinpour, C.M., Hayden, K.A., Unger, J.M., et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 26 (2008), 112–120.
88. Thompson, I.M. Jr., Tangen, C.M., Paradelo, J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006), 2329–2335.
89. Briganti, A., Karnes, J.R., Da Pozzo, L.F., et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55 (2009), 261–270.
90. Touijer, K.A., Mazzola, C.R., Sjoberg, D.D., Scardino, P.T., Eastham, J.A., Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65 (2014), 20–25.
91. Gandaglia, G., Trinh, Q.D., Hu, J.C., et al. The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the “post-dissemination” period. Eur J Surg Oncol 40 (2014), 1080–1086.
92. Rexer, H., Bartkowiak, D., Adjuvant radiotherapy in lymph-node-positive prostate cancer with low tumor burden after radical prostatectomy: multicenter randomized phase III trial on the effect of adjuvant radio therapy in patients with prostate cancer with or without positive margins after radical prostatectomy (RP) and lymph node metastasis with low tumor burden (micrometastases,
93. Kane, C.J., Amling, C.L., Johnstone, P.A., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61 (2003), 607–611.
94. Treglia, G., Ceriani, L., Sadeghi, R., Giovacchini, G., Giovanella, L., Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 52 (2014), 725–733.
95. Meredith, G., Wong, D., Yaxley, J., et al. The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 118:Suppl3 (2016), 39–55.
96. Stephenson, A.J., Scardino, P.T., Kattan, M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007), 2035–2041.
97. King, C.R., The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 84 (2012), 104–111.
98. Den, R.B., Feng, F.Y., Showalter, T.N., et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 89 (2014), 1038–1046.
99. Freedland, S.J., Choeurng, V., Howard, L., et al. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. Eur Urol 70 (2016), 588–596.
100. RADICALS. Radiotherapy and androgen deprivation in combination after local surgery. http://www.radicals-trial.org/.
101. ANZCTR. Radiotherapy following radical prostatectomy - Adjuvant Versus Early Salvage. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83910.
102. Zietman, A.L., DeSilvio, M.L., Slater, J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005), 1233–1239.
103. Cozzarini, C., Montorsi, F., Fiorino, C., et al. Need for high radiation dose (≥70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 75 (2009), 966–974.
104. Siegmann, A., Bottke, D., Faehndrich, J., et al. Salvage radiotherapy after prostatectomy—what is the best time to treat?. Radiother Oncol 103 (2012), 239–243.
105. Ohri, N., Dicker, A.P., Trabulsi, E.J., Showalter, T.N., Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio?. A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 48 (2012), 837–844.
106. Moghanaki, D., Koontz, B.F., Karlin, J.D., et al. Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. Cancer 119 (2013), 52–60.
107. Song, C., Kang, H.C., Kim, J.S., et al. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis. Strahlenther Onkol 191 (2015), 801–809.
108. Spiotto, M.T., Hancock, S.L., King, C.R., Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 69 (2007), 54–61.
109. Kim, B.S., Lashkari, A., Vongtama, R., Lee, S.P., Parker, R.G., Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer 3 (2004), 93–97.
110. Ost, P., Cozzarini, C., De Meerleer, G., et al. High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys 83 (2012), 960–965.
111. Soto, D.E., Passarelli, M.N., Daignault, S., Sandler, H.M., Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys 82 (2012), 1227–1232.
112. Jackson, W.C., Schipper, M.J., Johnson, S.B., et al. Duration of androgen deprivation therapy influences outcomes for patients receiving radiation therapy following radical prostatectomy. Eur Urol 69 (2016), 50–57.
113. Jang, J.W., Hwang, W.T., Guzzo, T.J., et al. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA. Int J Radiat Oncol Biol Phys 83 (2012), 1493–1499.
114. Trock, B.J., Han, M., Freedland, S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008), 2760–2769.
115. Gandaglia, G., Suardi, N., Cucchiara, V., et al. Penile rehabilitation after radical prostatectomy: does it work?. Transl Androl Urol 4 (2015), 110–123.
116. Gandaglia, G., Suardi, N., Gallina, A., et al. Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. J Urol 187 (2012), 569–574.
117. Kruser, T.J., Jarrard, D.F., Graf, A.K., et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 117 (2011), 2629–2636.
118. Wallis, C.J., Mahar, A.L., Choo, R., et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ, 352, 2016, i851.
119. Eifler, J.B., Humphreys, E.B., Agro, M., Partin, A.W., Trock, B.J., Han, M., Causes of death after radical prostatectomy at a large tertiary center. J Urol 188 (2012), 798–801.